White House strengthens biodefense amid fears that AI could supercharge biological threats

The White House is rebuilding its biodefense architecture after staffing cuts left the unit depleted, driven by concerns that AI could lower the barrier to bioweapons development. On May 5, 2025, Executive Order 14292 directed the Office of Science and Technology Policy to overhaul dual-use research oversight within 120 days, and a July 29, 2026 policy mandated an interagency group to monitor AI-biology intersections. OpenAI and Anthropic have acknowledged elevated biological weapons risks in their models, prompting voluntary testing.

Via lonelyplanet.com White House strengthens biodefense amid fears that AI could supercharge biological threats Staffing cuts left the administration's biosecurity apparatus threadbare, but new executive orders and policy directives signal a renewed push to close the gap. The White House is working to rebuild its biodefense architecture, driven by a convergence of two uncomfortable realities: a depleted team of biosecurity experts and a fast-moving AI landscape that has made the barrier to bioweapons development lower than at any point in history. The Washington Post reported the push on August 17, 2026, framing it as an effort by the Trump administration to reestablish defenses that had quietly eroded in the early months of the second term. How the gap opened By the time the Biden administration handed over the keys, the White House biodefense team had grown to roughly 30 specialists. Early in the second Trump term, staffing cuts drew that number down sharply, leaving the unit depleted and, at certain points, without any dedicated biosecurity personnel at all. AI capabilities were advancing in parallel, and the risks were not theoretical. OpenAI and Anthropic, two of the most prominent AI developers in the world, have both acknowledged that their models carry elevated biological weapons risks. Both companies support or actively conduct voluntary testing and evaluation of their systems for exactly these capabilities. What the administration is actually doing On May 5, 2025, the White House issued Executive Order 14292, directing the Office of Science and Technology Policy to overhaul oversight of dual-use research. The order gave OSTP 120 days to revise or replace the 2024 dual-use research oversight policy and to update frameworks for screening nucleic acid synthesis. The executive order also directed the administration to end certain categories of high-risk research conducted overseas. America’s AI Action Plan, published in July 2025, explicitly flagged dual-use biological capabilities as a priority concern. The plan called for a matured US biosecurity strategy that includes enhanced nucleic acid synthesis screening and a formal government process for evaluating AI models for biological risk. On July 29, 2026, the White House issued a policy on high-risk life sciences research instructing OSTP to convene an interagency group specifically tasked with monitoring developments at the intersection of biological sciences and AI. Why this is harder than it sounds The AI dimension adds a layer of complexity that no previous administration has had to navigate. The Food and Drug Administration oversees certain aspects of biological research. The Centers for Disease Control manages select agent programs. The National Security Council handles threat assessments. The intelligence community watches foreign programs. OSTP coordinates science policy. None of these entities has clear authority over an AI model developed by a private company and deployed globally. The July 2026 directive’s interagency coordination mandate is an attempt to create a connective layer across that fragmented landscape. Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy https://cryptobriefing.com/editorial-policy/ .